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Background: The 2007 Dartmouth Atlas of Cardiovascular Health Care noted significant variability of percutaneous coronary intervention 
(PCI) rates by Hospital Referral Region (HRR). Anti-anginal medications can treat coronary artery disease (CAD) and reduce the need for PCI. 
Appropriateness Criteria for Coronary Revascularization recommend maximizing anti-anginal medications before pursuing elective PCI. We 
hypothesized that greater use of anti-anginal medications would be associated with lower rates of PCI, due to symptom resolution with medical 
therapy.
Methods: Using data from the CathPCI Registry® and the Dartmouth Atlas, we examined patients undergoing elective PCI for stable CAD from 
January 1, 2009 through March 31, 2011 and calculated rates of aggressive anti-anginal therapy prior to PCI, defined as being on at least 2 of the 
following anti-anginal medications: beta blockers, calcium channel blockers, long acting nitrates, ranolazine, or other anti-anginal medicine. We 
analyzed rates of anti-anginal medications and regressed the rates of providing at least 2 anti-anginal medications within HRRs by the regions’ rates 
of PCI per 1,000 Medicare enrollees in 2007.
Results: Amongst 300,772 patient encounters, there were 32.1% of patients on no anti-anginal medications, 47.6% on 1 medication, 16.9% on 
2 medications and 3.4% on at least 3 anti-anginal medications. The rate of anti-anginal therapy (at least 2 medications) prior to PCI was 20.3%. 
Although substantial variability existed across HRRs in applying at least 2 anti-anginal therapies [interquartile range (IQR) 13.0% to 23.3%], there 
was no association between the rates of PCI [mean 10.2 per 1,000 Medicare enrollees, IQR 4.6 to 22.5] in each HRR and the rates of at least 2 
anti-angina medications before PCI [Spearman’s rho: 0.0341, p=0.57].
Conclusions: We found no association between the intensity of anti-anginal therapy and the use of PCI across HRRs, despite the variability of both. 
Other variables, besides the intensity of pre-PCI anti-anginal therapy, likely explain the variability of PCI.
